Verquvo 2.5 mg film-coated tablets

DRUG3 trials

Sponsors

Amsterdam UMC, Rigshospitalet, Karolinska University Hospital

Conditions

Heart failure with reduced ejection fraction (HFrEF)Treatment-resistant hypertensionUnequivocal epicardial and/or microvascular vasospastic angina

Phase 2

Vericiguat in Vasospastic Angina (ViVA)

RecruitingCTIS2022-502998-42-00

Amsterdam UMCUnequivocal epicardial and/or microvascular vasospastic angina

Start: 2025-02-10Target: 55Updated: 2026-01-21

A three-way cross-over phase IIa trial using L-citrulline and folic acid in combination with vericiguat and tadalafil in patients with treatment-resistant hypertension

Not yet recruitingCTIS2024-520231-33-00

Karolinska University HospitalTreatment-resistant hypertension

Target: 21Updated: 2025-11-27

Phase 4

ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with CardioMEMS™ HF System)

RecruitingCTIS2024-514111-10-00

RigshospitaletHeart failure with reduced ejection fraction (HFrEF)

Start: 2024-12-06Target: 17Updated: 2025-04-16